Page last updated: 2024-11-04

rofecoxib and Cardiovascular Diseases

rofecoxib has been researched along with Cardiovascular Diseases in 147 studies

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

ExcerptRelevanceReference
" We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer."9.12Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. ( Dunn, JA; Duvvuri, R; Iveson, C; Julier, P; Kerr, DJ; Langman, MJ; McConkey, CC; Midgley, RS; Smith, JL; Stanley, A; Stokes, JC, 2007)
"To assess the tolerability of rofecoxib compared with naproxen for treatment of osteoarthritis."9.10Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. ( Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS, 2003)
" We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis."9.09Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000)
"Using an intention-to-treat analysis of adjudicated CVT deaths, we analyzed detailed patient-level data collected during 3 randomized placebo-controlled trials of rofecoxib versus placebo that had been designed to define the drug's possible role in the prevention or treatment of Alzheimer disease."7.78Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. ( Avorn, J; Furberg, CD; Madigan, D; Mayer, JW; Sigelman, DW, 2012)
" To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials."7.71Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002)
" We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer."5.12Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. ( Dunn, JA; Duvvuri, R; Iveson, C; Julier, P; Kerr, DJ; Langman, MJ; McConkey, CC; Midgley, RS; Smith, JL; Stanley, A; Stokes, JC, 2007)
"To assess the tolerability of rofecoxib compared with naproxen for treatment of osteoarthritis."5.10Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. ( Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS, 2003)
" We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis."5.09Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000)
"Using an intention-to-treat analysis of adjudicated CVT deaths, we analyzed detailed patient-level data collected during 3 randomized placebo-controlled trials of rofecoxib versus placebo that had been designed to define the drug's possible role in the prevention or treatment of Alzheimer disease."3.78Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. ( Avorn, J; Furberg, CD; Madigan, D; Mayer, JW; Sigelman, DW, 2012)
"It can be postulated that in addition to the risk of heart attack and stroke, rofecoxib users were at increased risk of hemorrhage, in addition to other thrombotic and embolic adverse events, which was exacerbated in those taking blood thinners or NSAIDs."3.75Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002. ( Barry, WT; Bottone, FG, 2009)
" Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0."3.75Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009)
"The aim of this study was to examine the influence of regulatory measures and other external factors on the rate of ADR reporting in Italy, focusing on four situations occurring in the last 10 years: ACE inhibitor-induced cough; HMG-CoA reductase inhibitors ('statins') and rhabdomyolysis; nimesulide and hepatic toxicity; and cyclo-oxygenase (COX)-2 selective inhibitors ('coxibs') and increase in cardiovascular risk."3.74Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. ( Conforti, A; Leone, R; Montanaro, N; Moretti, U; Motola, D; Vaccheri, A; Vargiu, A; Velo, G, 2008)
"Using national data (2001-2003), this study explored the risk of acute myocardial infarction (AMI), angina, stroke and transient ischaemic attack (TIA) in long-term users of rofecoxib and celecoxib in Taiwan and compared this data with that for those using meloxicam."3.73Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. ( Hsiao, FY; Huang, WF; Shih, YT; Tsai, YW; Wen, YW, 2006)
" To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials."3.71Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002)
"Rofecoxib (Vioxx) was withdrawn from the market because of increased death from cardiovascular (CV) events."2.43Cardiovascular issues of COX-2 inhibitors and NSAIDs. ( Chowienczyk, P; Kirkham, B; Wong, M, 2005)
"Celecoxib was not associated with an elevated risk of vascular occlusion, summary relative risk 1."2.43Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. ( Henry, D; McGettigan, P, 2006)
" Indeed, both observational studies and randomised clinical trials showed that rofecoxib is associated with a significantly increased risk of acute myocardial infarction in patients receiving either high daily dosage (>25 mg/day) or for a long period of time (> 18 months)."2.42[Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?]. ( Scheen, AJ, 2004)
" Comparisons were made between patients taking rofecoxib and those taking either placebo, naproxen (an NSAID with near-complete inhibition of platelet function throughout its dosing interval), or another nonselective NSAIDs used in the development program (diclofenac, ibuprofen, and nabumetone)."2.41Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. ( Barr, E; Gertz, BJ; Konstam, MA; Reicin, A; Shapiro, D; Sperling, RS; Weir, MR, 2001)
" Patients prescribed CSIs (or NSAIDs) should be reviewed within the first few weeks of therapy to assess effectiveness, identify adverse effects and determine the need for ongoing therapy."2.41Considerations for the safe prescribing and use of COX-2-specific inhibitors. ( , 2002)
"The evidence is compelling for a role of inflammation in cardiovascular diseases; however, the chronic use of anti-inflammatory drugs for these indications has been disappointing."1.35Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. ( Aiyar, N; Behm, DJ; Bentley, RG; Coatney, RW; Doe, CP; Eybye, ME; Maniscalco, K; Olzinski, AR; Westfall, TD; Willette, RN; Zhao, S, 2009)
"Rofecoxib was withdrawn from the market worldwide because of concerns relating to cardiovascular safety."1.33Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme. ( Ashton, J; Harrison-Woolrych, M; Herbison, P; McLean, R; Slattery, J, 2005)
" Data on duration, dosage and indications were taken from the rofecoxib prescriptions."1.33[Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences]. ( van der Veen, WJ; van der Werf, GT, 2006)
"Rofecoxib was recalled in September 2004 when studies identified increased cardiovascular risk compared with placebo among patients taking rofecoxib."1.33The patient's perspective on the recall of Vioxx. ( Hawker, GA; Katz, JN; Solomon, DH, 2006)
" In addition, the cardiac toxicity of rofecoxib could be due to its unique chemical structure, its pharmacokinetics and tissue distribution, and/or the presence of toxic metabolites."1.32COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. ( Davies, NM; Jamali, F, 2004)

Research

Studies (147)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's137 (93.20)29.6817
2010's9 (6.12)24.3611
2020's1 (0.68)2.80

Authors

AuthorsStudies
Lee, TT1
Solomon, DH2
Kesselheim, AS1
Moore, N2
Miyajima, A1
Okamoto, M1
Muto, T1
Hirota, T1
McIntyre, WF1
Evans, G1
Anwar, A1
Anwar, IJ1
Delafontaine, P1
Sobel, M1
Madigan, D3
Wang, W1
Motola, D1
Vargiu, A1
Leone, R1
Conforti, A1
Moretti, U1
Vaccheri, A1
Velo, G1
Montanaro, N1
Jaksch, W1
Dejaco, C1
Schirmer, M1
Setakis, E1
Leufkens, HG2
van Staa, TP1
Baron, JA2
Sandler, RS2
Bresalier, RS2
Lanas, A2
Morton, DG1
Riddell, R2
Iverson, ER1
Demets, DL1
Bottone, FG1
Barry, WT1
Willette, RN1
Eybye, ME1
Olzinski, AR1
Behm, DJ1
Aiyar, N1
Maniscalco, K1
Bentley, RG1
Coatney, RW1
Zhao, S1
Westfall, TD1
Doe, CP1
Simon, LS2
White, WB1
Ray, WA1
Varas-Lorenzo, C1
Chung, CP1
Castellsague, J1
Murray, KT1
Stein, CM1
Daugherty, JR1
Arbogast, PG1
García-Rodríguez, LA1
Hsiao, FY2
Tsai, YW2
Huang, WF2
Liu, JY1
Li, N2
Yang, J1
Qiu, H1
Ai, D1
Chiamvimonvat, N1
Zhu, Y1
Hammock, BD1
Ross, JS2
Konstam, MA4
Egilman, DS2
Krumholz, HM2
Bäck, M1
Yin, L1
Ingelsson, E1
Sigelman, DW1
Mayer, JW1
Furberg, CD3
Avorn, J2
Jaeschke, R1
Gajewski, P1
Brozek, J1
Zhao, SZ1
Burke, TA1
Whelton, A1
von Allmen, H1
Henderson, SC1
Sonnenblick, EH1
Höcherl, K1
Dreher, F1
Kurtz, A1
Bucher, M1
Harley, C1
Wagner, S1
Spiegel, BM1
Targownik, L1
Dulai, GS1
Gralnek, IM1
Chiolero, A1
Maillard, MP1
Burnier, M2
Lisse, JR1
Perlman, M1
Johansson, G1
Shoemaker, JR1
Schechtman, J1
Skalky, CS1
Dixon, ME1
Polis, AB1
Mollen, AJ1
Geba, GP1
James, MJ1
Cleland, LG1
Krum, H1
Liew, D1
Aw, J1
Haas, S1
Fitzgerald, GA3
Adams, D1
Langton, PE1
Hankey, GJ1
Eikelboom, JW1
Egan, KM1
Lawson, JA1
Fries, S1
Koller, B1
Rader, DJ1
Smyth, EM1
Kondro, W1
Frantz, S1
Bijlsma, JW1
Zierenberg, O1
Lenzer, J1
Strand, V1
Håkansson, J1
Rosenberg, P1
Davies, NM1
Jamali, F1
Couzin, J3
Oakley, G1
Juhlin, R1
Scheen, AJ1
Kim, PS1
Reicin, AS2
Villalba, L1
Witter, J1
Wolfe, MM1
Hedner, T1
Melander, A1
Hansen, PR1
Callréus, T1
Meyer, CH1
Berenbaum, F1
Wardle, EN1
Kamen, B1
Kieran, M1
Senior, K1
Quan, H1
Bolognese, JA1
Oxenius, B1
Horgan, K1
Lines, C1
Morton, D1
Psaty, BM1
Drazen, JM2
Giannitsis, E1
Arellano, FM1
Weinberg, JM1
Rawson, NS1
Nourjah, P1
Grosser, SC1
Graham, DJ1
Smith, ER1
Weatherall, M1
Aldington, S1
Shirtcliffe, P1
Caldwell, B1
Beasley, R1
Jerie, P1
Laible, B1
Okie, S1
Eisenberg, RS1
Evensen, S1
Spigset, O1
Slørdal, L1
Maloney, DM1
Harrison-Woolrych, M1
Herbison, P1
McLean, R1
Ashton, J1
Slattery, J1
Bolten, WW1
Reiter, S1
Fortun, PJ1
Hawkey, CJ3
Florentinus, SR1
Heerdink, ER1
de Boer, A1
van Dijk, L1
Braunstein, N1
Polis, A1
Brophy, JM1
Khamsi, R1
Manthous, CA1
Daikh, DI1
Messerli, FH1
Sichrovsky, T1
Frazier, KC1
Araujo, LF1
Soeiro, Ade M1
Fernandes, Jde L1
Serrano Júnior, CV1
Bobadilla, RV1
Barnett, EM1
Randels, CL1
Wong, M1
Chowienczyk, P1
Kirkham, B1
Rainsford, KD1
Wadman, M2
Wu, R1
Laplante, MA1
de Champlain, J1
Curfman, GD1
Morrissey, S1
Bombardier, C2
Laine, L2
Burgos-Vargas, R2
Davis, B2
Day, R2
Ferraz, MB2
Hochberg, MC2
Kvien, TK2
Schnitzer, TJ2
Weaver, A1
Guo, ZR1
Wen, YW1
Shih, YT1
Dogné, JM1
Hanson, J1
Supuran, C1
Pratico, D1
Tegeder, I1
Geisslinger, G1
Sooriakumaran, P1
Nelson, NJ1
van der Veen, WJ1
van der Werf, GT1
Hawker, GA1
Katz, JN1
Nissen, SE1
Motsko, SP1
Rascati, KL1
Busti, AJ1
Wilson, JP1
Barner, JC1
Lawson, KA1
Worchel, J1
Armstrong, D1
Williams, D1
Singh, M1
Hind, C1
McGettigan, P1
Henry, D1
Marwali, MR1
Mehta, JL1
Mühlbauer, B1
Timm, J1
Scharnetzky, E1
Andersohn, F1
Schill, W1
Garbe, E1
Pigeot, I1
Höer, A1
Häussler, B1
Usher, C1
Bennett, K1
Teeling, M1
Feely, J1
Sibilia, J1
Deray, G3
Montalescot, G1
Valat, JP2
Héloire, F2
Zarraga, IG1
Schwarz, ER1
Presler, AH1
Jugdutt, BI1
Ashworth, AJ1
Tabrizchi, R1
Depont, F1
Fourrier, A1
Merlière, Y1
Droz, C1
Amouretti, M1
Bégaud, B1
Bénichou, J1
Moride, Y1
Velo, GP1
Sturkenboom, M1
Blin, P1
Hellstrom, HR1
Salzberg, DJ1
Weir, MR2
Kerr, DJ1
Dunn, JA1
Langman, MJ1
Smith, JL1
Midgley, RS1
Stanley, A1
Stokes, JC1
Julier, P1
Iveson, C1
Duvvuri, R1
McConkey, CC1
Martínez-González, J1
Badimon, L1
Vinsonneau, U1
Brondex, A1
Mansourati, J1
Saraux, A1
Cornily, JC1
Arlès, F1
Godon, P1
Quiniou, G1
Sukel, MP1
van der Linden, MW1
Chen, C1
Erkens, JA1
Herings, RM1
Mayer, TV1
Reicin, A2
Shapiro, D3
Stienburg, KL1
Patrono, C2
Patrignani, P1
García Rodríguez, LA1
Gotlieb, D1
Comarow, A1
Sperling, RS2
Barr, E2
Gertz, BJ1
Yu, Q1
Sharma, RA1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of [NCT00282386]Phase 32,586 participants (Actual)Interventional1999-12-23Completed
A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073]Phase 2/Phase 384 participants (Actual)Interventional2017-04-04Completed
Phase III, Randomized, Double Blind, Placebo Controlled Study of Rofecoxib in Colorectal Cancer Patients Following Adjuvant Chemotherapy[NCT00031863]Phase 30 participants Interventional2001-02-28Completed
Pre-Emptive Analgesic Effects of a Selective COX-2 Inhibitor (Rofecoxib) in the Oral Surgery Model[NCT00026819]Phase 2150 participants Interventional2001-11-30Completed
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614]Phase 258 participants (Actual)Interventional2003-03-31Completed
A Placebo-Controlled, Double-Blind, Randomized Study of the Potential Interaction Between Aspirin and Ibuprofen or Celecoxib.[NCT00565500]Phase 424 participants (Actual)Interventional2003-04-30Completed
Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients[NCT00749645]Phase 260 participants (Actual)Interventional2006-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

37 reviews available for rofecoxib and Cardiovascular Diseases

ArticleYear
Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.
    Drug safety, 2020, Volume: 43, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiotoxicity; Cardiovascular Diseases; Cyclooxygenase 2 I

2020
Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs.
    Trends in cardiovascular medicine, 2015, Volume: 25, Issue:8

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies;

2015
4 years after withdrawal of rofecoxib: where do we stand today?
    Rheumatology international, 2008, Volume: 28, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Contraindications; Cyclooxygenase

2008
COX-2 selective inhibitors and heart health.
    Postgraduate medicine, 2005, Volume: 117, Issue:1 Suppl

    Topics: Adult; Cardiovascular Diseases; Celecoxib; Child; Cyclooxygenase 2 Inhibitors; Humans; Hypertension;

2005
Differences between COX-2-specific inhibitors: clinical and economic implications.
    The American journal of managed care, 2002, Volume: 8, Issue:15 Suppl

    Topics: Aged; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibit

2002
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
    Annals of internal medicine, 2003, May-20, Volume: 138, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib;

2003
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?
    Expert opinion on drug safety, 2002, Volume: 1, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Ce

2002
Cardiovascular effects of selective cyclooxygenase-2 inhibitors.
    Expert review of cardiovascular therapy, 2004, Volume: 2, Issue:2

    Topics: Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Celecoxib; Clinical Trials as To

2004
[Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?].
    Revue medicale de Liege, 2004, Volume: 59, Issue:10

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy

2004
Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
    Clinical laboratory, 2005, Volume: 51, Issue:1-2

    Topics: Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; Cardio

2005
[COX-2 inhibitors--one step forward and two steps back].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2005, Apr-07, Volume: 125, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibito

2005
Life after Vioxx: the clinical implications.
    Hospital medicine (London, England : 1998), 2005, Volume: 66, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Clinical Tr

2005
The safety of rofecoxib.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Case-Control Studi

2005
Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?
    The American journal of cardiology, 2005, Sep-15, Volume: 96, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cycloox

2005
[Cardiovascular events: a class effect by COX-2 inhibitors].
    Arquivos brasileiros de cardiologia, 2005, Volume: 85, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi

2005
COX-2 inhibitors and the heart: putting risk in perspective.
    Advance for nurse practitioners, 2005, Volume: 13, Issue:11

    Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis

2005
Cardiovascular issues of COX-2 inhibitors and NSAIDs.
    Australian family physician, 2005, Volume: 34, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Protocols; Cyclooxygenase

2005
Introduction - The coxib controversies.
    Inflammopharmacology, 2005, Volume: 13, Issue:4

    Topics: Animals; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Sulfones

2005
[Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2005, Volume: 40, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclo

2005
Coxibs and cardiovascular side-effects: from light to shadow.
    Current pharmaceutical design, 2006, Volume: 12, Issue:8

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase

2006
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
    Naunyn-Schmiedeberg's archives of pharmacology, 2006, Volume: 373, Issue:1

    Topics: Cardiovascular Diseases; Celecoxib; Cell Proliferation; Clinical Trials as Topic; Cyclooxygenase Inh

2006
COX-2 inhibitors and the heart: are all coxibs the same?
    Postgraduate medical journal, 2006, Volume: 82, Issue:966

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi

2006
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
    JAMA, 2006, Oct-04, Volume: 296, Issue:13

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi

2006
COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.
    Thrombosis and haemostasis, 2006, Volume: 96, Issue:4

    Topics: Animals; Blood Platelets; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inh

2006
[What do we know about the cardiovascular toxicity of the NSAIDs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celeco

2006
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas

2006
Coxibs and heart disease: what we have learned and what else we need to know.
    Journal of the American College of Cardiology, 2007, Jan-02, Volume: 49, Issue:1

    Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhib

2007
What have we learnt from Vioxx?
    BMJ (Clinical research ed.), 2007, Jan-20, Volume: 334, Issue:7585

    Topics: Cardiovascular Diseases; Compensation and Redress; Cyclooxygenase 2 Inhibitors; Drug Industry; Human

2007
COX-2 inhibitors and cardiovascular risk.
    Sub-cellular biochemistry, 2007, Volume: 42

    Topics: Blood Pressure; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lactones;

2007
Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.
    Current pharmaceutical design, 2007, Volume: 13, Issue:22

    Topics: Atherosclerosis; Cardiovascular Diseases; Consumer Product Safety; Cyclooxygenase 2; Cyclooxygenase

2007
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35 Suppl 1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cerebrovascular Disorders; Coronar

2006
Cardiovascular disease in patients with spondyloarthropathies.
    Joint bone spine, 2008, Volume: 75, Issue:1

    Topics: Antirheumatic Agents; Atherosclerosis; Atrioventricular Block; Cardiovascular Diseases; Comorbidity;

2008
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
    The Journal of clinical investigation, 2001, Volume: 108, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiova

2001
The coxibs, selective inhibitors of cyclooxygenase-2.
    The New England journal of medicine, 2001, Aug-09, Volume: 345, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena

2001
The coxibs, selective inhibitors of cyclooxygenase-2.
    The New England journal of medicine, 2001, Aug-09, Volume: 345, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena

2001
The coxibs, selective inhibitors of cyclooxygenase-2.
    The New England journal of medicine, 2001, Aug-09, Volume: 345, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena

2001
The coxibs, selective inhibitors of cyclooxygenase-2.
    The New England journal of medicine, 2001, Aug-09, Volume: 345, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena

2001
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
    Circulation, 2001, Nov-06, Volume: 104, Issue:19

    Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu

2001
Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer.
    QJM : monthly journal of the Association of Physicians, 2002, Volume: 95, Issue:5

    Topics: Arachidonic Acid; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; C

2002
Considerations for the safe prescribing and use of COX-2-specific inhibitors.
    The Medical journal of Australia, 2002, Apr-01, Volume: 176, Issue:7

    Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase In

2002

Trials

5 trials available for rofecoxib and Cardiovascular Diseases

ArticleYear
Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.
    Lancet (London, England), 2008, Nov-15, Volume: 372, Issue:9651

    Topics: Cardiovascular Diseases; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Data Interpretation, Sta

2008
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
    Annals of internal medicine, 2003, Oct-07, Volume: 139, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors

2003
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
    The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11

    Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin

2005
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
    The New England journal of medicine, 2007, Jul-26, Volume: 357, Issue:4

    Topics: Adenoma; Aged; Cardiovascular Diseases; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cyclooxygenase

2007
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
    The New England journal of medicine, 2000, 11-23, Volume: 343, Issue:21

    Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors

2000
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
    The New England journal of medicine, 2000, 11-23, Volume: 343, Issue:21

    Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors

2000
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
    The New England journal of medicine, 2000, 11-23, Volume: 343, Issue:21

    Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors

2000
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
    The New England journal of medicine, 2000, 11-23, Volume: 343, Issue:21

    Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors

2000

Other Studies

105 other studies available for rofecoxib and Cardiovascular Diseases

ArticleYear
Fool Me Twice? The Reemergence of Rofecoxib and the Orphan Drug Act.
    Annals of internal medicine, 2019, 10-15, Volume: 171, Issue:8

    Topics: Arthritis; Cardiovascular Diseases; Chronic Pain; Hemophilia A; Humans; Lactones; Orphan Drug Produc

2019
Disruption of elastic lamellae in aorta and dysfunction of vaso-regulation by rofecoxib in rats.
    The Journal of toxicological sciences, 2013, Volume: 38, Issue:5

    Topics: Administration, Oral; Age Factors; Amino Acids; Animals; Aorta; Arterial Pressure; Cardiovascular Di

2013
The Vioxx® legacy: Enduring lessons from the not so distant past.
    Cardiology journal, 2014, Volume: 21, Issue:2

    Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Approval; History, 21st Century; Humans;

2014
Causal Inference for Meta-Analysis and Multi-Level Data Structures, with Application to Randomized Studies of Vioxx.
    Psychometrika, 2017, Volume: 82, Issue:2

    Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Male; Meta-Analysis as Topic

2017
Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
    Drug safety, 2008, Volume: 31, Issue:7

    Topics: Adverse Drug Reaction Reporting Systems; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Di

2008
Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib.
    Arthritis and rheumatism, 2008, Aug-15, Volume: 59, Issue:8

    Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Databases, Factual; D

2008
Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002.
    Current medical research and opinion, 2009, Volume: 25, Issue:6

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Interactions; Dr

2009
Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.
    The Journal of pharmacology and experimental therapeutics, 2009, Volume: 330, Issue:3

    Topics: Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase 2; C

2009
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Circulation. Cardiovascular quality and outcomes, 2009, Volume: 2, Issue:3

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C

2009
Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
    Clinical therapeutics, 2009, Volume: 31, Issue:11

    Topics: Aged; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Drug Util

2009
Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events.
    Proceedings of the National Academy of Sciences of the United States of America, 2010, Sep-28, Volume: 107, Issue:39

    Topics: Animals; Biomarkers; Bleeding Time; Blood Coagulation; Blood Platelets; Cardiovascular Diseases; Cyc

2010
Persistence of cardiovascular risk after rofecoxib discontinuation.
    Archives of internal medicine, 2010, Dec-13, Volume: 170, Issue:22

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Administration S

2010
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
    European heart journal, 2012, Volume: 33, Issue:15

    Topics: Atrial Fibrillation; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic

2012
Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies.
    American heart journal, 2012, Volume: 164, Issue:2

    Topics: Adverse Drug Reaction Reporting Systems; Alzheimer Disease; Cardiovascular Diseases; Cyclooxygenase

2012
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
    Circulation, 2002, Jul-30, Volume: 106, Issue:5

    Topics: Aspirin; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Hu

2002
Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    The American journal of managed care, 2002, Volume: 8, Issue:15 Suppl

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cross-Sectional S

2002
Cyclooxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure.
    Hypertension (Dallas, Tex. : 1979), 2002, Volume: 40, Issue:6

    Topics: Animals; Blood Pressure; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase

2002
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Clinical therapeutics, 2003, Volume: 25, Issue:1

    Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular D

2003
[Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
    MMW Fortschritte der Medizin, 2003, Mar-13, Volume: 145, Issue:11

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu

2003
Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen.
    Annals of internal medicine, 2003, Oct-07, Volume: 139, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors

2003
Matters of the heart: assessing the cardiovascular safety of new drugs.
    American heart journal, 2003, Volume: 146, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxy

2003
Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib.
    Journal of medical ethics, 2004, Volume: 30, Issue:2

    Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Industry; Ethics Committees, Research; Huma

2004
Coxibs and cardiovascular disease.
    The New England journal of medicine, 2004, Oct-21, Volume: 351, Issue:17

    Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis

2004
Unnecessary withdrawal of Vioxx.
    The New Zealand medical journal, 2004, Oct-22, Volume: 117, Issue:1204

    Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Drug Approval; Humans; Lactones; Sulfones

2004
Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events.
    The Medical journal of Australia, 2004, Nov-15, Volume: 181, Issue:10

    Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lactones; Product Surveillance, Postmark

2004
COX-2-derived prostacyclin confers atheroprotection on female mice.
    Science (New York, N.Y.), 2004, Dec-10, Volume: 306, Issue:5703

    Topics: Animals; Antioxidants; Arteriosclerosis; Cardiovascular Diseases; Cells, Cultured; Cyclooxygenase 2;

2004
Lawsuits mount in wake of rofecoxib (Vioxx) withdrawal.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2004, Nov-23, Volume: 171, Issue:11

    Topics: Canada; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Industry; Humans; Lactones; Liabili

2004
Vioxx risk could signify trouble in class.
    Nature reviews. Drug discovery, 2004, Volume: 3, Issue:11

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy

2004
[Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
    Nederlands tijdschrift voor geneeskunde, 2004, Oct-30, Volume: 148, Issue:44

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans;

2004
[Slime fight in the lay media. Were the Vioxx fatal cases kept secret?].
    MMW Fortschritte der Medizin, 2004, Oct-21, Volume: 146, Issue:43

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Controlled Clinical Trials as Topi

2004
Public interest group accuses FDA of trying to discredit whistleblower.
    BMJ (Clinical research ed.), 2004, Nov-27, Volume: 329, Issue:7477

    Topics: California; Cardiovascular Diseases; Consumer Organizations; Lactones; Sulfones; United States; Unit

2004
A world without Vioxx: to COX-2 or not to COX-2?
    Cleveland Clinic journal of medicine, 2004, Volume: 71, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Gastroi

2004
[The case of Vioxx requires consideration].
    Lakartidningen, 2004, Nov-04, Volume: 101, Issue:45

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Drug and Narcotic Control; Drug In

2004
COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2004, Oct-29, Volume: 7, Issue:3

    Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis

2004
Clinical trials. Nail-biting time for trials of COX-2 drugs.
    Science (New York, N.Y.), 2004, Dec-03, Volume: 306, Issue:5702

    Topics: Alzheimer Disease; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib; Controlled Clinical

2004
Lessons from the withdrawal of rofecoxib: Observational studies should not be forgotten.
    BMJ (Clinical research ed.), 2004, Dec-04, Volume: 329, Issue:7478

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Drug Approval; Humans; Lactones; R

2004
[MSD about Vioxx--important to learn from the experience without hindsight].
    Lakartidningen, 2004, Nov-11, Volume: 101, Issue:46

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Drug and Narcotic Control; Drug In

2004
Rofecoxib, Merck, and the FDA.
    The New England journal of medicine, 2004, Dec-30, Volume: 351, Issue:27

    Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; History, 20th Cent

2004
Rofecoxib, Merck, and the FDA.
    The New England journal of medicine, 2004, Dec-30, Volume: 351, Issue:27

    Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Drug Labeling; His

2004
Rofecoxib, Merck, and the FDA.
    The New England journal of medicine, 2004, Dec-30, Volume: 351, Issue:27

    Topics: Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Drug Interact

2004
[Reflections on COX, Vioxx and Relifex. Increased cardiovascular risk following selective COX-2 inhibition].
    Lakartidningen, 2004, Nov-25, Volume: 101, Issue:48

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Gastrointestinal Diseas

2004
[Rofecoxib--a recall with implications].
    Ugeskrift for laeger, 2004, Dec-06, Volume: 166, Issue:50

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Drug and Narcotic Control; Humans;

2004
Under surveillance.
    Nature biotechnology, 2005, Volume: 23, Issue:1

    Topics: Biotechnology; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Hum

2005
Sentinel systems are needed for long term adverse drug reactions.
    BMJ (Clinical research ed.), 2005, Jan-29, Volume: 330, Issue:7485

    Topics: Adverse Drug Reaction Reporting Systems; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Approv

2005
[Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
    Klinische Monatsblatter fur Augenheilkunde, 2005, Volume: 222, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Colonic Polyps; Costs a

2005
VIOXX and cardiovascular events: a class effect?
    Joint bone spine, 2005, Volume: 72, Issue:1

    Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lactones; Randomized Controlled Trials a

2005
Coxibs and caution.
    Journal of the Royal Society of Medicine, 2005, Volume: 98, Issue:2

    Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Humans; Lactones; Sulfones

2005
Don't throw out the baby with the bathwater!
    Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:2

    Topics: Advertising; Cardiovascular Diseases; Child; Child Welfare; Clinical Trials as Topic; Cyclooxygenase

2005
COX-2 inhibitors: cancer prevention or cardiovascular risk?
    The Lancet. Oncology, 2005, Volume: 6, Issue:2

    Topics: Adenoma; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy

2005
[Vioxx: reasons for a premature retirement].
    Medecine sciences : M/S, 2005, Volume: 21, Issue:1

    Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis

2005
COX-2 inhibitors--lessons in drug safety.
    The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11

    Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase In

2005
COX-2 inhibitors--a lesson in unexpected problems.
    The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11

    Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis

2005
The withdrawal of rofecoxib.
    Pharmacoepidemiology and drug safety, 2005, Volume: 14, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic;

2005
Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Science (New York, N.Y.), 2005, Feb-25, Volume: 307, Issue:5713

    Topics: Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cy

2005
The lessons of Vioxx.
    Cutis, 2005, Volume: 75, Issue:1

    Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis

2005
Factors associated with celecoxib and rofecoxib utilization.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:4

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies;

2005
Cyclooxygenase-2 inhibitors and cardiovascular risk.
    The Canadian journal of cardiology, 2005, Volume: 21, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Australia; Canada; Cardiovascular Diseases; Celecoxib; Cycl

2005
COX-2 inhibitors--first, do no harm.
    The New Zealand medical journal, 2005, Mar-11, Volume: 118, Issue:1211

    Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Humans; Lactones; New

2005
[VIOXX written off--and what next? COX-2 inhibitors and cardiovascular diseases].
    Casopis lekaru ceskych, 2005, Volume: 144, Issue:1

    Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lactones; Sulfones

2005
COX-2 inhibitors and cardiovascular toxicity: a class effect?
    South Dakota journal of medicine, 2005, Volume: 58, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibito

2005
Raising the safety bar--the FDA's coxib meeting.
    The New England journal of medicine, 2005, Mar-31, Volume: 352, Issue:13

    Topics: Advertising; Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular

2005
Learning the value of drugs--is rofecoxib a regulatory success story?
    The New England journal of medicine, 2005, Mar-31, Volume: 352, Issue:13

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Approval; Drug In

2005
Institutional review boards must conduct safety review.
    Human research report, 2005, Volume: 20, Issue:2

    Topics: Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Clinical Trials Data Monitoring Commit

2005
Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme.
    Drug safety, 2005, Volume: 28, Issue:5

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; F

2005
[Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
    Zeitschrift fur Rheumatologie, 2005, Volume: 64, Issue:4

    Topics: Antirheumatic Agents; Cardiovascular Diseases; Consumer Product Safety; Cyclooxygenase Inhibitors; D

2005
The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Pharmacoepidemiology and drug safety, 2005, Volume: 14, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Comorbidity; Cyclooxyge

2005
Report of specific cardiovascular outcomes of the ADVANTAGE trial.
    Annals of internal medicine, 2005, Jul-19, Volume: 143, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Gastroi

2005
Cardiovascular risk associated with celecoxib.
    The New England journal of medicine, 2005, Jun-23, Volume: 352, Issue:25

    Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Data Interpretation, Statistical; Hum

2005
Painkiller verdict shows mistrust of Merck.
    Nature, 2005, Aug-25, Volume: 436, Issue:7054

    Topics: Arrhythmias, Cardiac; Cardiovascular Diseases; Disclosure; Drug Industry; Humans; Lactones; Male; Su

2005
The Vioxx debacle revisited.
    The American journal of medicine, 2005, Volume: 118, Issue:9

    Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Humans; Lactones; Physician's Rol

2005
The Vioxx debacle revisited.
    The American journal of medicine, 2005, Volume: 118, Issue:9

    Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lactones; Product Surveillance, Postmark

2005
The lessons of Vioxx.
    The New England journal of medicine, 2005, Sep-29, Volume: 353, Issue:13

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug In

2005
Journal grows suspicious of Vioxx data.
    Nature, 2005, Dec-15, Volume: 438, Issue:7070

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Drug Industry; Humans; Lactones; Periodicals as T

2005
Scientific publishing. Echoing other cases, NEJM says Vioxx Safety data withheld.
    Science (New York, N.Y.), 2005, Dec-16, Volume: 310, Issue:5755

    Topics: Authorship; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Databases,

2005
[Role of cyclo-oxygenases in the effects of angiotensin II].
    Medecine sciences : M/S, 2006, Volume: 22, Issue:1

    Topics: Angiotensin II; Animals; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lacton

2006
Expression of concern reaffirmed.
    The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11

    Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Lactones; Myocard

2006
Response to expression of concern regarding VIGOR study.
    The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11

    Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Data Interpretation, Statistical; Gastrointestinal D

2006
Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
    Drug safety, 2006, Volume: 29, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina Pectoris; Cardiovascular Diseases; Celecoxib;

2006
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks.
    Harvard health letter, 2005, Volume: 30, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi

2005
Celecoxib shown effective in preventing colon polyps.
    Journal of the National Cancer Institute, 2006, May-17, Volume: 98, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib

2006
[Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences].
    Nederlands tijdschrift voor geneeskunde, 2006, May-06, Volume: 150, Issue:18

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors;

2006
The patient's perspective on the recall of Vioxx.
    The Journal of rheumatology, 2006, Volume: 33, Issue:6

    Topics: Aged; Cardiovascular Diseases; Communication; Cyclooxygenase 2 Inhibitors; Drug and Narcotic Control

2006
Adverse cardiovascular effects of rofecoxib.
    The New England journal of medicine, 2006, Jul-13, Volume: 355, Issue:2

    Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Humans; Lact

2006
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
    Drug safety, 2006, Volume: 29, Issue:7

    Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Stu

2006
Adverse cardiovascular effects of rofecoxib.
    The New England journal of medicine, 2006, Jul-13, Volume: 355, Issue:2

    Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Humans; Lact

2006
How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".
    Wall Street journal (Eastern ed.), 2006, May-15

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug Industry; Edito

2006
The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland.
    British journal of clinical pharmacology, 2006, Volume: 62, Issue:3

    Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Approval; Humans; Lactones; Practice Patt

2006
[Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib].
    Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8

    Topics: Cardiovascular Diseases; Cerebrovascular Disorders; Confidence Intervals; Controlled Clinical Trials

2006
[How many harmed by rofecoxib in Germany?].
    Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8

    Topics: Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Confidence Intervals; Controlled Clin

2006
[Overestimated].
    Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Controlled Clinical Trials as Topi

2006
Characterizing new users of NSAIDs before and after rofecoxib withdrawal.
    British journal of clinical pharmacology, 2007, Volume: 63, Issue:4

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Cycloo

2007
Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
    Harvard heart letter : from Harvard Medical School, 2006, Volume: 17, Issue:2

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxy

2006
Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
    Circulation, 2007, Jan-23, Volume: 115, Issue:3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib

2007
Cardiac risks with COX-2 inhibitors.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2007, Feb-13, Volume: 176, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Dose-Res

2007
Coxibs: can this class of drugs survive?
    Vascular health and risk management, 2005, Volume: 1, Issue:1

    Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Evidence-Bas

2005
Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.
    Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:8

    Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxi

2007
Man on a mission.
    Nature, 2007, May-31, Volume: 447, Issue:7144

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; History, 21st Century; Humans;

2007
A proposed fairer method for conducting rofecoxib trials.
    Medical hypotheses, 2007, Volume: 69, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxy

2007
Keeping science on top in drug evaluation.
    The New England journal of medicine, 2007, Aug-16, Volume: 357, Issue:7

    Topics: Advisory Committees; Cardiovascular Diseases; Conflict of Interest; Cyclooxygenase Inhibitors; Dexfe

2007
Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal.
    Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cohort Stud

2008
Merck's Careful Study of Vioxx.
    The American journal of cardiology, 2008, Apr-01, Volume: 101, Issue:7

    Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Sulfones; Treatment Outcome

2008
Rofecoxib (Vioxx): a year in review.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2001, Apr-03, Volume: 164, Issue:7

    Topics: Adverse Drug Reaction Reporting Systems; Canada; Cardiovascular Diseases; Enzyme Inhibitors; Humans;

2001
Celecoxib-- the debate ranges on.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2001, Volume: 91, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Insurance Cover

2001
Pain relief at a price. A blow to the heart?
    U.S. news & world report, 2001, Sep-03, Volume: 131, Issue:8

    Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors;

2001
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
    The American journal of cardiology, 2002, Jan-15, Volume: 89, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Clinical T

2002